|
Price: $0.0250
$-0.02 
-39.904%
|
| Day's High:
| $0.0397
| Week Perf:
| -63.66 %
|
| Day's Low: |
$ 0.02 |
30 Day Perf: |
-93.41 % |
| Volume (M): |
108,503 |
52 Wk High: |
$ 4.96 |
| Volume (M$): |
$ 2,713 |
52 Wk Avg: |
$2.97 |
| Open: |
$0.04 |
52 Wk Low: |
$0.02 |
|
|
| Market Capitalization (Millions $) |
5 |
| Shares
Outstanding (Millions) |
182 |
| Employees |
300 |
| Revenues (TTM) (Millions $) |
122 |
| Net Income (TTM) (Millions $) |
-103 |
| Cash Flow (TTM) (Millions $) |
-160 |
| Capital Exp. (TTM) (Millions $) |
5 |
Viewray Inc
Viewray Inc is a publicly traded medical technology company headquartered in Cleveland, Ohio. The company designs and manufactures advanced radiation therapy systems for the treatment of cancer. Viewray's patented technology utilizes magnetic resonance imaging (MRI) to guide radiation therapy, resulting in more accurate and precise treatment.
Viewray's flagship product is the MRIdian system, which combines an MRI scanner with a linear accelerator (linac) to provide real-time imaging during radiation therapy delivery. This allows clinicians to monitor the tumor and surrounding tissues in real-time, and adapt the treatment plan as necessary to account for any changes in the patient's anatomy or tumor size.
The MRIdian system has several unique features that set it apart from traditional radiation therapy systems. One of these is the ability to deliver radiation dose while the patient is in motion, which is particularly important for treating tumors in organs such as the lungs or liver that move as the patient breathes. Another is the ability to adjust the radiation beam continuously during treatment, an approach known as adaptive radiation therapy.
Viewray's technology has numerous advantages over traditional radiation therapy systems. For one, it allows for higher doses of radiation to be delivered to the tumor while minimizing damage to healthy tissues. This can improve outcomes for patients with certain types of cancer, such as prostate cancer. Additionally, because the MRIdian system uses MRI for imaging, it does not expose patients to ionizing radiation, which is a concern with other imaging modalities such as CT.
Viewray has a large and growing customer base, with installations of the MRIdian system in cancer centers throughout the world. The company has partnerships with several leading cancer institutions, including MD Anderson Cancer Center and the Mayo Clinic. Viewray's revenue has been steadily increasing, and the company is poised for continued growth as it expands its offerings and enters new markets.
Company Address: 1099 18th Street Suite 3000 Denver 80202 CO
Company Phone Number: 703-3210 Stock Exchange / Ticker: NASDAQ VRAY
| VRAY is expected to report next financial results on October 31, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Fonar Corporation
In the recent fiscal period, Fonar Corporation, a prominent player in the Medical Equipment and Supplies sector, reported disappointing financial results. However, despite the challenges faced, there are reasons to be cautiously optimistic about the company's future performance. This article will provide an in-depth analysis of Fonar Corporation's financials and evaluate its potential for recovery.
Financial Performance
Fonar Corporation experienced a significant drop in its earnings per share (EPS) from $0.23 to -$1.16 compared to the same period last year. Meanwhile, its revenue showed moderate growth, with a 3.885% increase to $25.78 million. This growth, however, falls short of the 4.79% expected by the Medical Equipment and Supplies sector as a whole.
|
|
Precision Optics Corporation Inc
Precision Optics Corporation Inc (POCI) has experienced a slight increase in its stock value over the past week, rising by 0.66%. Additionally, its stock currently trades 6.5% above its 52-week low. These figures indicate positive performance for the company in the stock market.
Examining POCI's financial report for the fourth quarter of 2023, it is evident that the company faced a net loss per share of $-0.11. This represents a decline from the $0.08 per share profit reported in the previous year. However, despite the loss, POCI saw a 4.811% increase in revenue, reaching $5.02 million compared to the corresponding reporting period the previous year.
|
|
Heart Test Laboratories Inc
Heart Test Laboratories Inc, a medical device manufacturing company, recently released its financial results for the first quarter of the 2024 earnings season. The figures demonstrate a significant decrease in loss per share compared to the previous year, as well as an improvement in earnings per share. Although the revenue remained unchanged, the company reported a lower net shortfall compared to the same reporting season the previous year. This article aims to provide an overview of Heart Test Laboratories Inc's Q1 2024 financial results and analyze them within the context of recent stock performance.
Financial Results:
Heart Test Laboratories Inc reported a loss per share of $-0.13 in the first quarter of 2024, a considerable improvement from the loss per share of $-0.28 in the same reporting season the previous year. Additionally, the company's earnings per share increased from $-0.16 in the previous reporting season. Despite these positive developments, the revenue for Q1 2024 remained unchanged at $0.00 million, both compared to the same reporting season a year before and sequentially.
|
|
Sensasure Technologies Inc
Date: August 1, 2023
As the financial interval closing July 31, 2023 draws to a close, Sensasure Technologies Inc, a leading technology company, has achieved a significant milestone by reaching break-even at $0.00 per share. This marks an improvement from the same reporting period a year ago when the company also reported a break-even, and from the preceding reporting period.
However, while this is an encouraging development for Sensasure Technologies Inc, it is crucial to examine the context of the financial results to gain deeper insights.
|
|
Innovage Holding Corp
Innovage Holding Corp, a Medical Equipment and Supplies company, recently released its financial results for the fourth quarter of 2023. Despite reporting a loss of $0.08 per share, compared to $0.09 in the previous year, the company's revenue grew moderately by 2.322% to $176.87 million.
However, this revenue surge was lower than the average growth rate of 4.80% for the Medical Equipment and Supplies sector during the same period. Analysts believe that this slower growth may be due to a decline in demand, as evidenced by the decrease in accounts receivable to $24.3 million.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.57 $ |
| Revenues (TTM) |
0.67 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.45 $
|
| Book Value |
0.3 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.57 $
|
| Revenues (TTM) |
0.67 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.45 $
|
| Book Value |
0.3 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
